Previous 10 | Next 10 |
home / stock / roivw / roivw news
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 21, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that it will host a live investor call and webcast at 8:00 AM ET on Thursday, June 22 to review results from the chronic period of TUSCANY-2, a large global Pha...
ADORING 1 met the primary and all secondary endpoints, consistent with the positive topline results from the Phase 3 ADORING 2 trial reported in March, marking Roivant’s 10 th consecutive positive Phase 3 study since 2019 45.4% of subjects receiving VTAMA achieved the primary end...
Roivant to develop PF-06480605 (now RVT-3101), a potential first in class, fully human monoclonal antibody that blocks tumor necrosis factor-like ligand 1A (TL1A), a cytokine believed to play a key role in inflammation and fibrosis RVT-3101 is currently being evaluated in a large global Phase...
Expected cash runway extended into the second half of calendar year 2025 First major PBM/payer contract signed for VTAMA, effective October 1 Over 54,000 VTAMA prescriptions written by approximately 6,400 prescribers since launch show strong demand, with fiscal Q2 2022 n...
NEW YORK and BASEL, Switzerland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Affivant, a biotechnology company dedicated to developing novel immune-oncology approaches to activate and enable the innate immune system to fight cancer, will present a poster at the 37 th Annual Meeting of The Society...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the pricing of its primary and secondary ...
BASEL, Switzerland, LONDON, NEW YORK, and BOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten pu...
Investor call and webcast scheduled for Monday, November 14 at 8:00 a.m. EST Roivant will present at investor conferences in November BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced...
Three healthcare investor conferences in September across Boston, New York and London Roivant Investor Day will take place virtually on September 28 th starting at 11 a.m. EDT BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Roivant Sc...
Early launch data for VTAMA ® (tapinarof) with approximately 14,000 prescriptions written by more than 3,000 unique prescribers in initial eleven weeks of launch shows strong demand for first topical novel chemical entity for plaque psoriasis in 25 years The Journal of ...
News, Short Squeeze, Breakout and More Instantly...
Roivant Sciences Ltd. Warrant Company Name:
ROIVW Stock Symbol:
NASDAQ Market:
Roivant Sciences Ltd. Warrant Website:
BASEL, Switzerland and LONDON and NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provided a business update. Once-daily brepocitinib produced the best Treatment Failure...
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31...
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 million Sumitomo Pharma repurchase reduces shares outstanding by 9% In the ...